戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t, and another was resistant to quinupristin-dalfopristin.
2 se the therapeutic potential of quinupristin-dalfopristin.
3 howed reduced susceptibility to quinupristin-dalfopristin.
4 aecium with cross-resistance to quinupristin-dalfopristin, a drug for vancomycin-resistant E. faecium
5 fically against such organisms, quinupristin/dalfopristin and linezolid, have been approved for use i
6  Among these are the new agents quinupristin/dalfopristin and linezolid.
7 n, tigecycline, daptomycin, and quinupristin-dalfopristin, and better specificity for ampicillin, van
8 resistance to the streptogramin quinupristin-dalfopristin in Enterococcus faecium isolates from chick
9 however, as the clinical use of quinupristin-dalfopristin increases.
10 de semisynthetic glycopeptides, quinupristin-dalfopristin, oxazolidinones and everninomycins.
11         Three hundred sixty-one quinupristin-dalfopristin (Q-D)-resistant Enterococcus faecium (QDREF
12 fections, namely, linezolid and quinupristin/dalfopristin (Q/D).
13 and their semisynthetic derivatives, such as dalfopristin-quinupristin (Synercid), are used to treat
14 y exposure is associated with a quinupristin-dalfopristin resistance gene and inducible quinupristin-
15 n resistance gene and inducible quinupristin-dalfopristin resistance in human fecal E. faecium.
16                    Constitutive quinupristin-dalfopristin resistance was absent in human E. faecium,
17                                 Quinupristin-dalfopristin resistance was found in 51 to 78% of E. fae
18                       Inducible quinupristin-dalfopristin resistance was more common in samples from
19      Constitutive and inducible quinupristin-dalfopristin resistance were assessed in E. faecium isol
20 n was associated with inducible quinupristin-dalfopristin resistance.
21 ventional poultry isolates were quinupristin-dalfopristin resistant.
22                                 Quinupristin-dalfopristin-resistant E. faecium contaminates a large p
23                                 Quinupristin-dalfopristin-resistant E. faecium was isolated from 237
24   To determine the frequency of quinupristin-dalfopristin-resistant E. faecium, we used selective med
25 k factors for human carriage of quinupristin-dalfopristin-resistant E. faecium.
26 cin, linezolid, nitrofurantoin, quinupristin-dalfopristin, rifampin, tigecycline, and vancomycin.
27  novel streptogramin antibiotic quinupristin/dalfopristin (synercid) on cytokine production in vitro
28  to use of two new antibiotics, quinupristin/dalfopristin (Synercid), first marketed in the United St
29 n, chloramphenicol, vancomycin, quinupristin-dalfopristin (Synercid), rifampin, linezolid, and tetrac
30 lin, nitrofurantoin, linezolid, quinupristin/dalfopristin, tylosin tartrate, streptomycin, daptomycin
31 ation of the streptogramins quinupristin and dalfopristin was approved in the United States in late 1
32 ce to vancomycin, linezolid, or quinupristin-dalfopristin was seen.
33                                 Quinupristin/dalfopristin was the first such drug to be commercially